Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HOWARD A LIEBMAN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1134159775
CMS profile
5849
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,435.35

52 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,635.35 51
Consulting Fee $800.00 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HOWARD A LIEBMAN

NPI 1134159775 · CMS profile ID 5849

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1134159775?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HOWARD A LIEBMAN, NPI 1134159775, CMS profile ID 5849. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134159775?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). HOWARD A LIEBMAN, NPI 1134159775, CMS profile ID 5849. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134159775?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
HOWARD A LIEBMAN, NPI 1134159775, CMS profile ID 5849, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1134159775?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

52 matching records · $2,435.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 52 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–52 of 52.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Celgene Corporation $2.4801/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015320577 CMS
Incyte Corporation $20.6501/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044413945 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $51,206.93 34
PY2020 $22,504.93 8
PY2021 $16,527.57 12
PY2022 $34,973.26 52
PY2023 $2,435.35 52
PY2024 $17,114.51 55
PY2025 $13,574.21 103

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $250.00 1
PY2025 Principal investigator $119,239.33 48
PY2024 Principal investigator $102,417.96 45
PY2023 Principal investigator $164,336.39 22
PY2022 Principal investigator $132,945.63 20
PY2021 Principal investigator $67,169.52 9
PY2020 Principal investigator $32,221.98 2
PY2019 Principal investigator $86,832.12 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

49 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $1,200.00 12/10/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226101853
Principal investigator 1 SANOFI US SERVICES INC. $20.00 12/03/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226101807
Principal investigator 1 SANOFI US SERVICES INC. $20.00 12/03/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226101813
Principal investigator 1 SANOFI US SERVICES INC. $27.00 12/03/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226101823
Principal investigator 1 SANOFI US SERVICES INC. $27.00 12/03/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226101829
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,350.00 11/21/2025 Covered Recipient Teaching Hospital
KECK HOSPITAL OF USC
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia No dispute reported 06/30/2026 1223267149
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 11/21/2025 Covered Recipient Teaching Hospital
KECK HOSPITAL OF USC
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia No dispute reported 06/30/2026 1223267151
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,150.00 11/21/2025 Covered Recipient Teaching Hospital
KECK HOSPITAL OF USC
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia No dispute reported 06/30/2026 1223267153
Principal investigator 1 SANOFI US SERVICES INC. $27.00 11/07/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226101818
Principal investigator 1 SANOFI US SERVICES INC. $600.00 11/07/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226101843
Principal investigator 1 SANOFI US SERVICES INC. $8,062.99 10/28/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226101870
Principal investigator 1 ARGENX US, INC. $4,040.55 10/23/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237160962
Principal investigator 1 SANOFI US SERVICES INC. $500.00 10/20/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226101837
Principal investigator 1 SANOFI US SERVICES INC. $1,100.00 10/20/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226101848
Principal investigator 1 SANOFI US SERVICES INC. $2,250.00 10/13/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226101859
Principal investigator 1 SANOFI US SERVICES INC. $3,300.00 10/13/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226101864
Principal investigator 1 SANOFI US SERVICES INC. $20.00 09/30/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226088825
Principal investigator 1 SANOFI US SERVICES INC. $27.00 09/30/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226088848
Principal investigator 1 SANOFI US SERVICES INC. $600.00 09/25/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226088856
Principal investigator 1 SANOFI US SERVICES INC. $12,094.48 07/31/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226088866
Principal investigator 1 SANOFI US SERVICES INC. $20.00 07/22/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226088818
Principal investigator 1 SANOFI US SERVICES INC. $27.00 07/22/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226088830
Principal investigator 1 SANOFI US SERVICES INC. $27.00 07/15/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226088843
Principal investigator 1 SANOFI US SERVICES INC. $27.00 07/10/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226088836
Principal investigator 1 SANOFI US SERVICES INC. $1,200.00 07/10/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226088861
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $29,150.00 07/07/2025 Covered Recipient Teaching Hospital
KECK HOSPITAL OF USC
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia No dispute reported 06/30/2026 1223267131
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,160.00 07/07/2025 Covered Recipient Teaching Hospital
KECK HOSPITAL OF USC
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia No dispute reported 06/30/2026 1223267133
Recipient GENZYME CORPORATION $250.00 06/21/2025 Covered Recipient Physician Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226082354
Principal investigator 1 ARGENX US, INC. $23,350.00 06/12/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants with Primary Immune Thrombocytopenia No dispute reported 06/30/2026 1237160952
Principal investigator 1 SANOFI US SERVICES INC. $27.00 05/30/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226088765
Principal investigator 1 SANOFI US SERVICES INC. $54.00 05/14/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226088777
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 05/08/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226088790
Principal investigator 1 SANOFI US SERVICES INC. $27.00 05/08/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226088922
Principal investigator 1 SANOFI US SERVICES INC. $5,942.94 05/02/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226088794
Principal investigator 1 ARGENX US, INC. $159.00 05/01/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants with Primary Immune Thrombocytopenia No dispute reported 06/30/2026 1237160959
Principal investigator 1 SANOFI US SERVICES INC. $600.00 04/24/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226088783
Principal investigator 1 SANOFI US SERVICES INC. $54.00 04/10/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226088771
Principal investigator 1 SANOFI US SERVICES INC. $20.00 04/04/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226088910
Principal investigator 1 SANOFI US SERVICES INC. $27.00 04/04/2025 Non-covered Recipient Entity
Usc General Depository
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226088915
Principal investigator 1 SANOFI US SERVICES INC. $1,200.00 03/13/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226142786
Principal investigator 1 SANOFI US SERVICES INC. $1,200.00 03/06/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226142781
Principal investigator 1 SANOFI US SERVICES INC. $500.00 01/30/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226142762
Principal investigator 1 SANOFI US SERVICES INC. $750.00 01/30/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226142767
Principal investigator 1 SANOFI US SERVICES INC. $1,100.00 01/30/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226142770
Principal investigator 1 SANOFI US SERVICES INC. $1,100.00 01/30/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226142773
Principal investigator 1 SANOFI US SERVICES INC. $7,854.37 01/30/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226142776
Principal investigator 1 SANOFI US SERVICES INC. $1,200.00 01/22/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226142759
Principal investigator 1 SANOFI US SERVICES INC. $20.00 01/17/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226142752
Principal investigator 1 SANOFI US SERVICES INC. $27.00 01/17/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) No dispute reported 06/30/2026 1226142755